ImmuCell Corporation (ICCC) Financial Statements (2024 and earlier)

Company Profile

Business Address 56 EVERGREEN DR
PORTLAND, ME 04103
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9795,79210,1857,9468,7742,521
Cash and cash equivalents9795,79210,1856,9506,2932,521
Short-term investments    9962,481 
Receivables2,1851,7592,6941,8481,637949
Inventory, net of allowances, customer advances and progress billings7,8126,0393,0902,0932,5182,332
Inventory7,8126,0393,0902,0932,5182,332
Prepaid expense 364 253218143
Other current assets 58     
Other undisclosed current assets 422951741477
Total current assets:11,03413,99516,26512,15713,1896,421
Noncurrent Assets
Operating lease, right-of-use asset4,5712,1951,1091,220 
Property, plant and equipment27,57628,44226,89426,75525,26626,028
Intangible assets, net (including goodwill)134153172191210229
Goodwill969696969696
Intangible assets, net (excluding goodwill)38577696115134
Derivative instruments and hedges      40
Other noncurrent assets11,4707726262713
Total noncurrent assets:43,75030,86628,20128,19325,50326,310
Other undisclosed assets (10,976)     
TOTAL ASSETS:43,80844,86144,46640,35038,69232,731
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,1242,0011,6141,3501,2211,221
Taxes payable2   
Employee-related liabilities586525400358
Accounts payable888790745602572604
Accrued liabilities1,0441,067828515193
Other undisclosed accounts payable and accrued liabilities19314419913798165
Debt1,4291,039812760  
Other undisclosed current liabilities644321081011,2751,344
Total current liabilities:4,1973,0722,5342,2112,4952,565
Noncurrent Liabilities
Long-term debt and lease obligation, including:10,5409,1919,3549,8727,1478,421
Long-term debt, excluding current maturities  9,1918,3278,7377,1478,421
Other undisclosed long-term debt and lease obligation10,540     
Liabilities, other than long-term debt4,0772,217  59 
Operating lease, liability4,0772,2171,0271,135 
Derivative instruments and hedges, liabilities     59 
Other undisclosed noncurrent liabilities   (1,027)(1,135)  
Total noncurrent liabilities:14,61811,4099,3549,8727,2058,421
Total liabilities:18,81514,48111,88912,0839,70110,986
Equity
Equity, attributable to parent24,99330,38032,57728,26628,99121,744
Common stock781781781730730566
Treasury stock, value(138)(147)(158)(175)(188)(205)
Additional paid in capital36,35735,97835,69231,37231,13222,696
Accumulated other comprehensive income (loss)     (44)30
Accumulated deficit(12,007)(6,232)(3,739)(3,660)(2,638)(1,343)
Total equity:24,99330,38032,57728,26628,99121,744
TOTAL LIABILITIES AND EQUITY:43,80844,86144,46640,35038,69232,731

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues17,47218,56819,24315,34213,72310,986
Cost of revenue
(Cost of Goods and Services Sold)
(13,602)(10,919)(10,587)(8,479)(6,983)(5,792)
Gross profit:3,8697,6498,6566,8636,7405,194
Operating expenses(9,617)(9,948)(8,399)(8,243)(7,694)(6,640)
Operating income (loss):(5,748)(2,299)257(1,380)(954)(1,447)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(22)(187)(327)348(314)(413)
Interest and debt expense(476)(349)(314)(8)(432)(428)
Loss from continuing operations before equity method investments, income taxes:(6,246)(2,835)(383)(1,040)(1,699)(2,288)
Other undisclosed income from continuing operations before income taxes4763493148432428
Loss from continuing operations before income taxes:(5,770)(2,486)(69)(1,032)(1,267)(1,860)
Income tax expense (benefit)(5)(8)(9)10(28)(462)
Loss from continuing operations:(5,775)(2,494)(78)(1,022)(1,296)(2,322)
Loss before gain (loss) on sale of properties:(78)(1,022)(1,296)(2,322)
Net loss:(5,775)(2,494)(78)(1,022)(1,296)(2,322)
Net income attributable to noncontrolling interest  2,49478   
Other undisclosed net loss attributable to parent  (2,494)(78)   
Net loss available to common stockholders, diluted:(5,775)(2,494)(78)(1,022)(1,296)(2,322)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(5,775)(2,494)(78)(1,022)(1,296)(2,322)
Other comprehensive income (loss)    44(74)31
Comprehensive loss:(5,775)(2,494)(78)(978)(1,370)(2,291)
Comprehensive income, net of tax, attributable to noncontrolling interest  2,49478   
Other undisclosed comprehensive loss, net of tax, attributable to parent   (78)   
Comprehensive loss, net of tax, attributable to parent:(5,775) (78)(978)(1,370)(2,291)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: